targeting flt3 in patients with relapsed/refractory aml
Published 4 years ago • 91 plays • Length 7:26Download video MP4
Download video MP3
Similar videos
-
6:38
relapsed/refractory flt3-mutated aml
-
1:09
dr. altman on gilteritinib in patients with relapsed/refractory aml
-
4:13
utilizing flt3 inhibitors in relapsed/refractory aml
-
2:28
dr. levis on gilteritinib in relapsed/refractory flt3-mutated aml
-
2:15
targeting flt3 in aml
-
1:12
gilteritinib relapse leads to loss of flt3-tkd mutation in patient with aml
-
5:07
relapsed vs. refractory data for flt3 inhibitors in aml
-
1:06
gilteritinib monotherapy shows potential for treatment of relapsed/refractory flt3 aml
-
1:18
dr. levis discusses the ideal use of quizartinib in flt3-itd aml
-
4:05
long-term challenges with flt3 inhibition in aml
-
7:40
targeting flt3 mutations in aml: differentiating first- and second-generation flt3 inhibitors
-
29:07
newly diagnosed aml: hitting the right target
-
0:49
treatment avenues for patients with r/r flt3-mutated aml: optimizing flt3 inhibitors
-
1:37
emerging mutations at relapse in flt3-mutated r/r aml on gilteritinib
-
8:36
flt3 mutational status can change between diagnosis and relapse in patients with aml
-
6:43
flt3 mutations’ impact on prognosis and treatment in aml
-
1:50
mark levis, md, on why the flt3 target is important in aml
-
4:26
emerging targeted agents in aml
-
4:47
the use of flt3 inhibitors in aml